Previous 10 | Next 10 |
Your immune system is constantly working to clean up faulty cells and damaged tissues. It's working, right now, to mop up pathogenic microbes and cancer cells before they can gain a foothold in your body. The search-and-destroy capabilities of immune cells have long made them ideal candidates fo...
SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in December: Piper...
Introduction I have covered companies developing immunotherapy treatments, with a focus on T cell therapies. While I have no doubt T cell therapies will be the next pillar in cancer treatments, current generation of therapies are plagued with various limitations. For example, approved CA...
Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
Iovance Biotherapeutics (NASDAQ: IOVA ) jumps 4.5% in premarket trading after reporting 41% objective response rate in 42 patients in Cohort 2 of Phase 2 lifileucel metastatic melanoma study C-144-01 in patients who were primary refractory to prior anti-PD-1/L1 therapy. More news ...
- 41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy - - Median duration of response (DOR) was not reached as as...
Now is a great time to have biotech stocks in your portfolio. While biotech investing can be scary, because the small-cap companies are often unprofitable research-and-development labs, this is also where a lot of the cutting-edge science is happening. Let's see how Mirati Therapeutics (NA...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were soaring 12.5% higher as of 11:27 a.m. EST on Friday. The nice jump came after the biotech announced updated data from a phase 2 clinical study evaluating lifileucel in treating metastatic melanoma. These results, presented at the Societ...
Dermira (NASDAQ: DERM ) +29% on apparent reaction to AnaptysBio's etokimab flop in a mid-stage atopic dermatitis study. More news on: Dermira, Inc., ObsEva SA, Sientra, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.86%Change Percent:
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 18:24:26 ET No investor likes it when one of their stocks is hit with a recommendation downgrade from an analyst. That was the dynamic behind Iovance Biotherapeutics ' (NASDAQ: IOVA) more than 2% decline in value on Monday. A onetime Iovance bull has considerably cooled o...
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and...
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...